-
The vaccine candidate includes an antigen in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialisation team, along with Dynavax’s advanced adjuvant CpG 1018.
-
Dr. Saul Faust, who is helping lead the study, said the research will start first in Britain but aims to recruit a total of 30,000 people in six countries around the world.
-
The vaccine supplies for the global market will be produced by RDIF's international partners in India, Brazil, China, South Korea and other countries.
-
Regulatory approval was being sought for the vaccine to progress to Phase 3 clinical trials before the end of the year.
-
SII and ICMR are conducting phase II/III clinical trial of the vaccine at 15 different centres across the country.
-
Hyderabad: The Covid-19 vaccine development is happening at a much faster pace when compared to other vaccines and it is pushing the innovation and manufacturing capabilities of developed and developing countries. Speaking at the 28th Annual Hysea Innovation Summit, Bharat Biotech MD Dr Krishna Ella said that the pandemic vaccine coming out in 12 months […]
-
Collaboration will allow Dr Reddy’s to identify and use some of the Biotechnology Industry Research Assistance Council’s clinical trial centres
-
The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3)
-
The coronavirus dominated the opening minutes of the Trump-Biden face-off with President Trump terming the contagion a “worldwide problem”.
-
The World Health Organisation (WHO) has identified 42 candidate vaccines in clinical trials, ten of which are in the most advanced "phase 3" stage.
-
The first phase of vaccination will be carried out on the groups of people with highest risk of COVID-19 infections.
-
This will be a multi-centre and randomised controlled study, which will include safety and immunogenicity study, Dr Reddy’s said in a statement.
-
Whenever the Union government makes a vaccine available, the Apollo Hospitals will leverage its robust pan-India web of 19 medicine supply hubs with cold chain facilities.
-
With over one million coronavirus deaths and nearly 40 million cases worldwide, regions like Europe that suppressed the first outbreak are again facing tough choices on how to control a new wave.
-
"The possibility of reinfections could have significant implications for our understanding of Covid-19 immunity, especially in the absence of an effective vaccine."
-
Bovine Adenovirus, also known as BAdV, is a member of the Adenoviridae family that causes disease in cattle.
-
The annual budget is expected to contain a wage subsidy to get unemployed young Australians back to work.
-
Rather than vaccinating everyone, the aim is to "vaccinate everyone at risk," Kate Bingham, Chair of the UK Vaccine Taskforce, told the Financial Times, while detailing the aim of the programme.
-
Hyderabad-headquartered company is currently conducting Phase II human trials of Covaxin after receiving Drug Controller General of India nod
-
Frontline healthcare workers in govt, private sector likely to be first ones to receive it